Statin-associated myopathy with normal creatine kinase levels.
BACKGROUND
Muscle symptoms in patients who are treated with statins and have normal creatine kinase levels are not well understood.


OBJECTIVE
To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use.


METHODS
Case reports from preliminary analysis of an ongoing clinical trial.


METHODS
Clinical research center in a community hospital.


METHODS
Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use.


METHODS
1) Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength.


RESULTS
All four patients repeatedly distinguished blinded statin therapy from placebo. Strength testing confirmed weakness during statin therapy that reversed during placebo use. Muscle biopsies showed evidence of mitochondrial dysfunction, including abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy when they were not receiving statins. Creatine kinase levels were normal in all four patients despite the presence of significant myopathy.


CONCLUSIONS
Some patients who develop muscle symptoms while receiving statin therapy have demonstrable weakness and histopathologic findings of myopathy despite normal serum creatine kinase levels.
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D000069059:Atorvastatin; D001706:Biopsy; D003402:Creatine Kinase / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008148:Lovastatin / Q000009:adverse effects; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced* / Q000201:enzymology* / Q000473:pathology; D010146:Pain / Q000139:chemically induced; D011758:Pyrroles / Q000009:adverse effects; D019821:Simvastatin / Q000009:adverse effects
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D008148:Lovastatin; D000069059:Atorvastatin; D019821:Simvastatin; D003402:Creatine Kinase